Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
841
A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity
Published 2025“…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [<sup>68</sup>Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”
-
842
A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity
Published 2025“…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [<sup>68</sup>Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”
-
843
-
844
-
845
-
846
-
847
-
848
Univariate and Multivariate analysis of risk factors for nerve injury 90-days after TKA.
Published 2025Subjects: -
849
-
850
-
851
-
852
-
853
-
854
Characteristics of HACE respondents by year.
Published 2025“…</p><p>Results</p><p>Overall patient satisfaction with general practice declined significantly over the 10 years, with mean positive scores dropping from 90.1% in 2011/12 to 70.5% in 2021/22. …”
-
855
-
856
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
857
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
858
-
859
-
860
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: